- U.S. and Australian institutional research collaborations
- Two clinical-stage candidates, one advanced pre-clinical stage
- Current focus on the improvement and extension of lives of prostate cancer patients with metastatic disease
Filamon is commencing with three drug candidates:
FLM-JG1 & FLM-c2 and FLM- BT2
All three involve ground-breaking discoveries that have eluded major pharma companies.
Our strategy is considerably de-risked with FLM-c2 already in the clinic and FLM-JG1 a repurposed drug with global marketing approval.
Together, Filamon believes all three technologies hold the key to halting the march of a cancer that kills an estimated 300,00 men globally each year.